HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+5.41%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$141M
AUM Growth
+$141M
(+4.8%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
1.6%
Top 10 Holdings %
Top 10 Hldgs %
55.72%
Holding
161
New
36
Increased
33
Reduced
7
Closed
45
Top Buys
Top Sells
| 1 |
IPHI
INPHI CORPORATION
IPHI
|
$3.84M |
| 2 |
RP
RealPage, Inc.
RP
|
$3.37M |
| 3 |
iShares MSCI India ETF
INDA
|
$2.29M |
| 4 |
Genworth Financial
GNW
|
$1.92M |
| 5 |
Alibaba
BABA
|
$1.83M |
Sector Composition
| 1 | Technology | 32.85% |
| 2 | Healthcare | 32.22% |
| 3 | Financials | 6.7% |
| 4 | Communication Services | 6.68% |
| 5 | Consumer Discretionary | 4.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
26
DELISTED
Invitae Corporation
NVTA
| $906K | 0.64% |
26,870
+10,831
| +68% | +$365K |
|
27
Kymera Therapeutics
KYMR
$3.1B
| $901K | 0.64% |
18,587
+4,646
| +33% | +$225K |
|
28
Zymeworks
ZYME
$1.07B
| $883K | 0.63% |
25,452
+4,450
| +21% | +$154K |
|
29
argenx
ARGX
$44.2B
| $879K | 0.62% |
2,919
+562
| +24% | +$169K |
|
|
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
| $876K | 0.62% |
10,631
+962
| +10% | +$79.3K |
|
31
Ocular Therapeutix
OCUL
$2.25B
| $875K | 0.62% |
+61,639
| New | +$875K |
|
|
IGMS
32
DELISTED
IGM Biosciences
IGMS
| $872K | 0.62% |
10,481
+1,560
| +17% | +$130K |
|
33
Baidu
BIDU
$33.1B
| $858K | 0.61% |
4,207
-559
| -12% | -$114K |
|
34
Relay Therapeutics
RLAY
$709M
| $851K | 0.6% |
23,250
+6,374
| +38% | +$233K |
|
35
Iovance Biotherapeutics
IOVA
$800M
| $845K | 0.6% |
32,458
+14,295
| +79% | +$372K |
|
36
C4 Therapeutics
CCCC
$182M
| $822K | 0.58% |
21,729
+4,142
| +24% | +$157K |
|
37
Syndax Pharmaceuticals
SNDX
$1.39B
| $821K | 0.58% |
47,814
+12,941
| +37% | +$222K |
|
38
Invesco DB Commodity Index Tracking Fund
DBC
$1.28B
| $816K | 0.58% |
42,396
| – | – |
|
39
Rocket Pharmaceuticals
RCKT
$358M
| $816K | 0.58% |
18,424
+4,088
| +29% | +$181K |
|
40
Olema Pharmaceuticals
OLMA
$432M
| $815K | 0.58% |
29,122
+14,667
| +101% | +$410K |
|
41
Mersana Therapeutics
MRSN
$34.8M
| $814K | 0.58% |
+59,906
| New | +$814K |
|
42
Amicus Therapeutics
FOLD
$2.42B
| $813K | 0.58% |
+84,371
| New | +$813K |
|
|
HZNP
43
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $813K | 0.58% |
8,679
+91
| +1% | +$8.52K |
|
44
PMV Pharmaceuticals
PMVP
$82.1M
| $812K | 0.58% |
23,758
+2,880
| +14% | +$98.4K |
|
45
Atea Pharmaceuticals
AVIR
$275M
| $801K | 0.57% |
+37,295
| New | +$801K |
|
46
Kura Oncology
KURA
$732M
| $801K | 0.57% |
38,428
+8,216
| +27% | +$171K |
|
47
Instil Bio
TIL
$196M
| $801K | 0.57% |
+41,436
| New | +$801K |
|
48
ARS Pharmaceuticals
SPRY
$1.08B
| $800K | 0.57% |
25,906
+11,839
| +84% | +$366K |
|
49
Ascendis Pharma
ASND
$12.1B
| $797K | 0.57% |
6,060
+555
| +10% | +$73K |
|
50
BridgeBio Pharma
BBIO
$9.91B
| $796K | 0.56% |
+13,056
| New | +$796K |
|